Compare CNTB & YCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNTB | YCY |
|---|---|---|
| Founded | 2012 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.4M | 152.7M |
| IPO Year | 2020 | 2025 |
| Metric | CNTB | YCY |
|---|---|---|
| Price | $0.62 | $10.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $5.71 | N/A |
| AVG Volume (30 Days) | ★ 599.6K | 37.8K |
| Earning Date | 11-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | $7,473.67 | N/A |
| Revenue Next Year | $240.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $9.90 |
| 52 Week High | $3.82 | $10.38 |
| Indicator | CNTB | YCY |
|---|---|---|
| Relative Strength Index (RSI) | 36.76 | 53.00 |
| Support Level | N/A | $9.95 |
| Resistance Level | $2.62 | N/A |
| Average True Range (ATR) | 0.07 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 33.75 | 44.57 |
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
AA Mission Acquisition Corp II is a blank check company formed for the purpose of effectuating a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities.